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Metabolic Derangements 
Adipose tissue releases a number of 
biologically active molecules that are 
thought to have a causative role in the 
pathogenesis of insulin resistance and 
vascular disease. Serum free fatty acids 
(FFAs) are generated by lipolysis 
(breakdown of stored triglycerides) . 
They are increased in obese individuals 
as a result of increased adipose tissue 
mass. FFAs induce insulin resistance, 
possibly by competing with glucose 
as an energy substrate and by having 
an inhibitory effect on insulin 
signaling. The liver takes up FFAs to 
synthesise triglycerides and packages 
them with proteins to form very low 
density lipoprotein (VLDL). FFAs 
therefore mediate the association 
between obesity and hepatic steatosis 
('fatty liver') and with 
hypertriglyceridaemia. 1 High serum 
triglycerides, in turn, result in small 
rlPn.~p T ,m ,;mrllow r-rm. Thf.'sf.' lipid 
abnormalities help explain the 
association between obesity and 
cardiovascular disease. 
FFAs are also thought to be 
deleterious to the f3 cells of the pancreas 
(lipotoxicity).2 They decrease the 
sensitivity of the pancreas to glucose, 
so that it secretes less insulin for a 
given plasma glucose concentration. J 
They also increase apoptosis 
(programmed cell death) of f3 cells, 
resulting in decreased f3 cell mass. 2 
The combination of increased insulin 
resistance and diminished f3 cell 
function predisposes to abnormal 
glucose tolerance and diabetes. 
Other cytokines releaseu by auipose 
tissue that contribute to increased 
cardiometabolic risk include tumour 
necrosis factor alpha (TNFalpha) , 
plasminogen activator inhibitor-l (PAI-
l) and interleukin-6 (11-6).4 These 
molecules decrease insulin sensitivity 
and are pro-inflammatory. PAI- I is 
also pro-thrombotic. Adipose tissue is 
also an endocrine organ, releasing a 
number of hormones. These include 
leptin (see below), resistin (which 
increases insulin resistance) and 
adiponectin (which decreases insulin 
resistance and inflammation). 
Metabolic Memory 
There is evidence that the metabolic 
milieu of adipose tissue early in life 
causes long-term or even permanent 
changes in their metabolic profile. 
Undernutrition in utero or in early 
postnatal life, especially if followed 
by unrestricted access to food later in 
life, leads to hyperplasia and 
hypertrophy of adipose tissue and a 
shift towards release of pro-
inflammatory cytokines and insulin 
resistance. 
Visceral vs Subcutaneous Fat 
Visceral fat is more strongly 
associated with cardiometabolic risk 
than subcutaneous fat. It secretes more 
FFA, PAI-l and IL-6. Furthermore, 
since these molecules are released 
directly into the portal rather than the 
systemic circulation, they have a 
greater effect on the live:r, their main 
site of action.5 Visceral fat is also more 
insulin resistant than subcutaneous fat. 
Furthermore the balance is shifted 
towards production of resistin rather 
than adiponectin. 
Visceral fat can be measured by 
CT scan, MRI or other specialized 
imaging techniques such as dual X-
Ray absorptiometry (DXi\). 
However, it is impractical to assess 
visceral obesity by using these 
modalities repeatedly in all patients. 
Fortunately, waist circumference has 
been found to be a useful indicator 
of visceral fat. Because it is so easy 
to measure, it is now used in the 
definition of 'central obesity ' or 
'abdominal obesity ' in most 
guidelines. 
Control of Food Intake 
Obesity is a very difficult condition 
to treat. It is caused by an interaction 
of genetic and environmental factors. 
A key to unraveling both its 
pathogenesis and its treatment, is an 
understanding of the physiological 
control of food intake and hence body 
weight. This is a very complex subject 
and only a very brief outline will be 
given here. The role of the 
endocannaboid system will be 
discussed in the next section. 
Two centres in the hypothalamus 
regulate the desire to eat. The feeding 
centre stimulates eating. The satiety 
centre inhibits the feeding centre. The 
activity of the hypothalamic centres 
is in turn regulated by a number of 
sensing mechanisms. The 
hypothalamus can thereby respond to 
ingestion of a meal (gut hormones), 
bouy fat mass (\ipostat or adipostat 
signals) and nutrient status (blood 
nutrient levels). 
A number of gut hormones inhibit 
food intake in response to food in the 
gastro-intestinal tract. 6 These include 
glucagon-like peptide I (GLP-l), 
cholecystokinin (CCK), pancreatic 
polypcptiuc (PP) and peptide YY. 
GLP-l and CCK also stimulate 
insulin release. Grehlin is a hormone 
secreted from the stomach in response 
to starvation and cachecia; it 
stimulates food intake as well as 
secretion of growth hormone from 
the pituitary. 
The hypothalamus also receives 
chemical signals about the body fat 
mass. Leptin is secreted by adipose 
tissue in proportion to its mass .7.8 
Leptin acts centrally to inhibit 
feeding. 9. 10 Adiponectin may also 
serve as an adiposity signal and 
inhibits feeding. Insulin levels 
correlate with adipose mass and are 
increased after meals. Like leptin, 
insul in's central action is probably 
to inhibit feeding. 
The hypothalamus can also sense 
directly the levels of certain nutrients 
in the blood; these include glucose 
and fats. For example, oleic acid (a 
constituent of olive oil) inhibits food 
intake." 
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